

Disclaimer



This presentation has been prepared by Almoosa Health (the "Company") for general use only and is not necessarily comprehensive as it has not been independently verified, nor is it considered or constitutes part of any invitation or inducement to engage in any investment activity, nor does it constitute an offer or solicitation to buy or subscribe for any securities, and does not constitute an offer, invitation or recommendation in connection with the purchase, ownership or sale of any securities of Almoosa Health.

The Company does not offer warranty, express or implied, regarding the accuracy, completeness, or correctness of the information or opinions contained in this presentation, and no person or legal entity should rely for any purpose on the information contained in this presentation. This presentation may include statements that are or may be considered "forward-looking statements" regarding the Company's financial position, results of operations and business, and certain of Almoosa Health's plans, expectations, assumptions, and objectives, which are for general update only and do not constitute an invitation or inducement to engage in any investment activity.

The information contained in this presentation, including but not limited to forward-looking statements, is current as of the date of this presentation and is not intended to provide any assurances about future outcomes.

By attending this presentation or receiving this document, you acknowledge and agree that you will not rely on the information contained herein without conducting your own due diligence and consulting with your own financial, legal, tax, or other professional advisors. The Company and its affiliates, officers, directors, employees, and agents expressly disclaim any liability for any direct or indirect loss or damage arising from the use of or reliance on this presentation or its contents. This presentation and its contents are proprietary to Almoosa Health. It may not be reproduced, redistributed, or disseminated, in whole or in part, without the prior written consent of the Company.

Presenters & Agenda



Malek Almoosa
Chief Executive Officer





Shailesh ChanderChief Financial Officer





Yousef Alyousef
Investor Relations Officer



- 1 Business overview
- **7** Financial review
- 3 Summary and outlook
- Q&A



Q3 2025 Highlights: Maintaining the growth trend



Revenue

Q3 9M

+15.5% YoY +18.2% YoY

EBITDA¹

Q3 9M

+11.3% YoY +37.9% YoY

Earnings per Share

Q3 9M

+42.7% YoY +204.3% YoY

Net Profit

03

9M

+84.9% YoY +282.6% YoY

Number of Clinics

Q3/9M

356

Number of Available Beds

Q3/9M

730

Maintaining the highest patient care and quality standards

Awards and accreditations

Council of Health Insurance

Reaccreditation for both Almoosa Specialist Hospital and Rehabilitation Hospital



Health Performance Award

Medical Coding Service Efficiency (Private Sector)



Gold Initiative Certificate

Almoosa Rehabilitation Hospital Patient Experience & Community Engagement Almoosa Specialist Hospital Innovation & Technology



Age Friendly Certificate

Almoosa Rehabilitation Hospital HIMSS 7
Reaccreditation

ICHOM Certificate









Important agreements signed



Global Health Exhibition

>130_K

visionaries gathered

At the Global Health Exhibition, Almoosa Health showcased not just growth, but identity sharing our roots, people, and healing stories under the shade of the sidr tree



Agreement Signing for Jubail Medical Center with Abdullah Al Othaim Investment Company

A high-quality medical center will expand Company's footprint in a high-growth urban area outside of Al Ahsa and responds to the increasing demand for advanced healthcare services



Partnership Agreement Signing for "Da Vinci Xi" Robotic Surgery System Supply with Gulf Medical Company

This step comes within Almoosa Health's strategic plan to expand its advanced services and elevate the quality of surgical care provided to patients



Agreement for Tele-Medicine Consultation with Al-Dawaa

Almoosa Health entered into a partnership with Al-Dawaa Pharmacies to offer telemedicine consultations, extending our care beyond hospital walls and bringing medical expertise closer to patients across the Kingdom



Almoosa Health signed an agreement with Bnoon, leader in "Assisted Reproductive Technology" services





5,000+

IVF cycles done annually

45% Success rates¹

Bnoon will be operating the IVF unit at Almoosa Specialist Hospital





DRG Transformation Framework: gaining experience and marking the progress



Almoosa Health invested in team's educational trip to Australia

The team visited leading institutions and engaged with experts from both public and private sectors as well as national DRG authorities to study best practices in AR-Diagnosis Related Groups (DRG), Clinical Documentation Improvement (CDI), and performance-based hospital financing

Key insights highlighted the importance of:

- Accurate clinical documentation
- Real-time CDI processes
- Multidisciplinary collaboration
- Data-driven funding models








A leader in comprehensive healthcare

Almoosa offers a world-class integrated health system that fosters wellness and healing across the care continuum, enabled by innovation and transformation















Delivering on our growth strategy: Medical Centers & Hospitals pipeline update

Projects completed

Aziziya Medical Center Al-Khobar Q3 2025

03 2025



Nakheel Medical Center Al-Ahsa



Projects in progress

Sulmaniyah Medical Center Al-Ahsa



Specialist Hospital Al-Khobar



Specialist Hospital Al-Hofuf



Q2 2027

Q1 2028

Q2 2026

Total Incurred cost till Q3¹

Projects yet to start

Jubail Q4 2026 Medical Center Jubail Industrial City



Medical Center 5 Al-Dammam Q4 2027



Nakheel Medical Center Al-Ahsa



37 clinics

6,100 m² Built-up area





JULY 30, 2025

Commencement of Operations

Specializations' list:

Dermatology and cosmetic

Primary Care

OB/GYN

General Pediatrics

Pediatric endocrinology

Allergy and immunology

ENT

Ophthalmology

Optometry

Dental

Emergency

Infusion center

General surgery

Adult endocrinology

Physical therapy services

Orthopedics



Aziziya Medical Center Al-Khobar



38 clinics

6,700 m² Built-up area

Commencement

of Operations

Specializations' list:

Primary Care

Dental

Pediatrics

Dermatology

OB/GYN

Ophthalmology

Hematology

Pediatric Psychiatry

Psychiatry

Endocrinology

Orthopedics

Physiotherapy

AUGUST 30, 2025









Sulmaniyah Medical Center Al-Ahsa



66 clinics

16,800 m² Built-up area





Q2, 2026
Construction completion

Current Status:

- Construction
- MOH
- Testing and Commissioning
 - CHIStaffing
- Licenses
- Completed In-progress

Specializations' list:

Pediatrics

Dermatology

OBS/GYN

Ophthalmology

ENT

Neurology

Endocrinology

Orthopedic

Pulmonary





Almoosa Specialist Hospital **Al-Hofuf**



200 clinics

140,000 m²

Built-up area

300 beds

Q2 2027

Construction completion

Current Status:

- Design
- Enabling Works
- Construction
- Testing & Commissioning
- Licenses
- MoH
- CHI
- Staffing
- Completed



Designer

HKS

Project

Project Consultant Supervision













Almoosa Specialist Hospital **Al-Khobar**



300 clinics

 $300,000 \, m^2$

Built-up area

Current Status:

- Design
- Construction
- Works
- Enabling Testing & Commissioning
 - Licenses
 - MoH
 - CHI
 - Staffing
- Completed In-progress

Project Designer



dar Perkins&Will

400 beds

Q1 2028

Construction completion



Project Enabling package & Consultant Supervision













Q3 2025 Financial Highlights



| 1 Steady revenue increase across segments | +15.5% YoY | 非 356.4 MN |
|--|-------------------|---------------|
| 2 Robust EBITDA increase | +11.2% YoY | 非 79.8 MN |
| 3 Strong Net Profit result | +84.9% YoY | 步 51.6 MN |
| 4 Slight decline in EBITDA margin | 22.4% | -0.9 pp. YoY |
| 5 Sustained improvement in Net Profit margin | 14.5% | +5.4 pp. YoY |
| 6 Robust Earnings per Share | +42.7% | 业 1.17 |



The Board has approved dividend of Sar 0.35 per share, amounting to 业15.5 million, for the third quarter of 2025

9M 2025 Financial Highlights



| 1 Resilient revenue growth across segments | +18.2% YoY | 共1028.3 MN |
|--|--------------------|---------------|
| 2 Robust EBITDA increase | +37.9% YoY | 共 232.7 MN |
| 3 Strong Net Profit increase | +282.6% YoY | 共 154.5 MN |
| 4 Further improvement in EBITDA margin | 22.6% | +3.2 pp. YoY |
| 5 Significant growth of Net Profit margin | 15.0% | +10.4 pp. YoY |
| 6 Robust Earnings per Share | +204.3% | |

| HMN | 9M 2024 | Δ% | 9M 2025 |
|-------------------------------------|---------------------------|-------------------------|---------------------------|
| Net Revenue | 870.2 | +18.2% | 1 028.3 |
| EBITDA ¹ (margin) | 168.8 <i>19.4%</i> | +37.9% 3.2 pp. | 232.7 <i>22.6%</i> |
| Net Profit (margin) | 40.4 <i>4.6%</i> | +282.6% 10.4 pp. | 154.5 <i>15.0%</i> |
| CAPEX (as % of revenue) | 172.5 <i>19.8%</i> | +92% | 409.2 <i>39.8%</i> |
| Earnings per share | 1.15 | +204.3% | 3.50 |


All segments contributing to robust performance



Well-balanced payer mix




Strong profits and gradual margin increase supported by operational excellence and efficient capital structure



Enhanced capital structure and debt optimization driving financial resilience










2025 & Medium-term guidance






















Appendix


Key investment highlights



Growing and underpenetrated healthcare sector relative to global benchmarks


Notable historical acceleration in healthcare expenditures, driven by private sector with robust growth outlook











An integrated, patient-centered health system delivering continuity of care

Integrated Healthcare Ecosystem



Preventative



Secondary



Tertiary

Report Acute Care



Tele-health

Preventative Care Services

- Screening program
- Timely referral
- G6PD (Regional basis)
- GBS in pregnancy
- Hearing tests for newborns
- Palivizumab test
- Tdap in pregnancy
- Retinal exam for diabetic patients
- Oncology prevention and education support

Primary Care Services

- Primary Care
- Obgyn
- Pediatrics
- Dental
- ENT
- Ophthalmology
- Dermatology
- Urgent care

Acute Care Services

- Nuclear medicine
- Sports Medicine
- Women Health
- IVF
- General surgery
- Ophthalmology
- Bariatric surgery
- Dentistry
- ENT
- Gastroenterology
- Nephrology
- Diabetes

Centers of Excellence

- Cardiology
- Orthopedics
- Oncology
- Pediatrics
- Neuroscience

Post-acute Care Services

- Neurology & Stroke recovery
- Spinal cord injury
- Adaptive Sport Rehabilitation.
- Musculoskeletal
- Pediatrics rehabilitation.
- Pain management
- Mental Health
- Home Healthcare

Tele-health Services

- Hospital at home
- Remote monitoring
- · Tele-medicine
- Virtual visits
- Mobile applications
- Tele-pharmacy

Almoosa Health's integrated model delivers coordinated care, continuous treatment, and superior outcomes through seamless patient-centered services within our dedicated network, capturing value throughout the patient experience



Building a healthier future

Environmental

Promoting environmental responsibility and building a greener future, through eco-friendly facilities

Pioneering Sustainable Architecture in Healthcare

Rehabilitation Hospital



The first LEED Platinum-certified

building in the Middle East

BIG 5

Sustainable Initiative of the Year

Finalist



The first hospital with the LEED Gold certificate in the KSA

Specialist Hospital

Almoosa Health was among the pioneers in introducing green buildings in the KSA







Waste Management System

With robust waste management system at its core, Almoosa excels in guiding businesses towards efficient waste reduction, recycling, and resource recovery practices.



Energy Efficiency

Facilities and IP units designed to maximize natural daylight, creating a bright and uplifting environment for the patients



Connection with nature

Thoughtfully designed outdoor spaces and terraces, providing Almoosa patients with therapeutic environment that promote healing



Strong social record and commitment

Environmental Social Social

Committed to invest in the society of Al-Ahsa as regional leader in community-based initiatives

Saudi Arabia's 95th National Day Celebration and Activities



Bringing employees and patients together in joy and national pride under the theme عِزْنا بطبعنا





Employees actively participated in a Handicrafts Workshop, creating traditional crafts that showcased local creativity and culture



Ardah sword dance performed in the Medical Center's hall to pay tribute to traditions

Cooking workshop

A fun cooking activity during Al Nakheel Medical Center opening embraced children from the local community, fostering engagement and joy among families



A Paramedic in Every School

Aims to train teachers on CPR and first aid to save students and deal correctly with emergency incidents

5 schools participated

650 students trained



Smile of Hope

Treating children with Cleft lip, to draw a smile of hope on their lips



Power of Art

Showcasing unique Saudi artwork within the Company facilities, to promote national artistic efforts



Fostering balanced leadership and strategic insight

Environmental Social Governance

Diverse governance structure ensures inclusive and effective decision-making across the organization

Board of Directors



Diverse board composition to provide robust challenge and oversight with **majority** being independent board members

Sub-committee structure and membership in line with CMA requirements and best practices

Reporting system



Clear, accurate, and timely disclosures on financial performance, as well as governance practices.

Oversight



Efficient policies and procedures, promoting business excellence and accountability.

Risk Management



Robust risk management frameworks to identify, assess, and address risks that could impact the Company's performance and reputation.

Ethics and Integrity



Responsibility for strategy and control with a commitment to the highest standards of **ethics and integrity**



Income statement

| 非 MN | Q3 2024 | Q3 2025 | % Chg. (Q3) | 9M 2024 | 9M 2025 | % Chg. (9M) |
|---|---------|---------|-------------|---------|---------|-------------|
| Revenue | 308.5 | 356.4 | +15.5% | 870.2 | 1028.3 | +18.2% |
| Cost of revenue | -210.4 | -238.9 | +13.6% | -618.4 | -700.0 | +13.2% |
| Gross profit | 98.1 | 117.4 | +19.8% | 251.8 | 328.3 | +30.4% |
| General and administrative expenses | -45.8 | -58.6 | +27.9% | -132.3 | -151.6 | +14.6% |
| Selling and distribution expense | -4.0 | -6.9 | +75.5% | -17.2 | -20.8 | +20.7% |
| Provision / (reversal) for impairment loss on accounts receivable | -0.9 | -0.9 | +5.3% | -3.3 | -2.7 | -18.1% |
| Other income | 4.1 | 4.6 | +13.2% | 9.8 | 11.4 | +16.5% |
| Other expenses | - 1 | 1.4 | - | - | -3.0 | - |
| Operating profit | 51.5 | 57.1 | +10.8% | 108.7 | 161.6 | +48.8% |
| Finance cost | -23.0 | -5.8 | -74.9% | -64.7 | -16.4 | -74.7% |
| Finance income | - | 1.1 | - | - | 7.8 | - |
| Share of profit from equity accounted investee | 0.3 | 0.4 | +29.3% | 0.6 | 0.4 | -39.0% |
| Profit before zakat | 28.7 | 52.7 | +83.5% | 44.6 | 153.4 | +243.6% |
| Zakat | -0.8 | -1.1 | +34.8% | -4.2 | 1.2 | -127.7% |
| Net Profit | 27.9 | 51.6 | +80.9% | 40.4 | 154.5 | +282.6% |

Balance sheet

| 业 MN | FY 2024 | Q3 2025 |
|-------------------------------|---------|---------|
| Property & equipment | 1,894.4 | 2,238.7 |
| Right of use assets | 16.6 | 90.6 |
| Intangible assets | 8.4 | 9.9 |
| Equity accounted investee | 9.0 | 9.3 |
| Total Non-Current Assets | 1,928.4 | 2,348.6 |
| Total Current Assets | 625.0 | 858.0 |
| Total Assets | 2,553.4 | 3,206.5 |
| Total Current Liabilities | 562.8 | 438.7 |
| Total Non-Current Liabilities | 1,272.9 | 822.7 |
| Total Liabilities | 1,835.7 | 1,261.4 |
| Total Equity | 717.7 | 1,945.1 |
| Total Liabilities And Equity | 2,553.4 | 3,206.5 |

Cash flow statement

| 北 MN | Q3 2024 | Q3 2025 |
|--|---------|---------|
| Net cash from operating activities | 143.5 | 119.1 |
| Net cash used in investing activities | -172.5 | -497.8 |
| Net cash from financing activities | 46.9 | 395.0 |
| Net change in cash and cash equivalents | 17.9 | 16.3 |
| Cash and cash equivalents at beginning of the period | 15.8 | 38.2 |
| Cash and cash equivalents at end of the period | 33.8 | 54.5 |



ir.almoosahealthgroup.org

Thank
you

